| Literature DB >> 33732838 |
Christopher L Robinson1, Sheetal K Sethupathi2, Janet A Fairley1, Brian K Link3, Vincent Liu1,4.
Abstract
Entities:
Keywords: LCT, large cell transformation; MF, mycosis fungoides; large cell transformation; lip ulcer; mycosis fungoides
Year: 2021 PMID: 33732838 PMCID: PMC7941007 DOI: 10.1016/j.jdcr.2021.01.023
Source DB: PubMed Journal: JAAD Case Rep ISSN: 2352-5126
Fig 1Clinical appearance of characteristic lesions. A, Wide and penetrating ulceration with yellow-black necrotic tissue at the base of the left upper cutaneous and mucosal lip with destruction and distortion of both the mucosal and cutaneous lip outlined by an erythematous rolling serpiginous plaque. B, Disseminated pink, scaly, thin, nummular plaques and patches, here depicted over the right thigh.
Fig 2Histopathology of lip ulcer. A, Scattered CD30-positive and ALK1-negative large atypical lymphoid infiltrates with associated mixed acute and chronic inflammation and necroinflammatory debris (Hematoxylin-eosin–stain; original magnification: ×20.) B, CD30-positive cells are highlighted. (CD30 immunostain; original magnification: ×20.)
Summary of literature documenting oral mycosis fungoides (MF) with large cell transformation (LCT)
| Case | Reference | Age at MF diagnosis (Dx) | Age at oral MF Dx | Sex | Oral mucosa involved | Cutaneous involvement | Treatment for oral MF | Treatment for cutaneous disease | Outcome |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kunishige et al. (2006) | 70 | 72 | M | Tongue | Erythroderma, keratoderma, and well-circumscribed, dome-shaped tumors on scalp, chin, and chest. Baseline-involved body surface area (BSA) was 27.15% (22% patches, 3.5% plaques, 1.65% tumors) | Local radiation therapy | Denileukin diftitox (for chronic lymphocytic leukemia), suberoylanilide hydroxamic acid, gemcitabine, local radiation therapy | Not provided |
| 2 | Kunishige et al. (2006) | 55 | 56 | F | Tongue | Hyperpigmented patches, evolving into plaques and tumors (86% BSA: 2% patches, 80% plaques, 6.4% tumors) | Boost radiation | Cyclophosphamide, methotrexate, etoposide, dexamethasone, gemcitabine, TSEB radiation | Death (4 months after appearance of tongue lesion) |
| 3 | Bittencourt et al. (2015) | 48 | 48 | M | Not specified | Plaques; oral large cell lymphoma presented simultaneously with skin lesions | Local radiation therapy, IFN | IFN | Alive with disease (at 9 months) (as of 2015) |
| 4 | Bassuner et al. (2016) | 63 | 67 | M | Tongue | Exfoliative erythroderma (90% BSA with 3:1 ratio of plaques to patches) | Electron beam radiation, bexarotene | Vorinostat; forodesine with minor partial response; combined modality with IFN-alpha plus bexarotene and extracorporeal photophoresis; TSEB radiation; alemtuzumab. | Alive, disease-free (as of 7 years after appearance of oral lesion) |
| 5 | Sultan et al. (2017) | Not provided | 68 | M | Tongue, buccal mucosa, hard palate | Sezary syndrome; multiple well-demarcated erythematous macules on the bilateral upper and lower distal extremities | Excisional biopsy, PUVA photochemotherapy | Ultraviolet light-B phototherapy, PUVA | Alive with disease (as of 2017) |
| 6 | Goggins et al. (2018) | 40 | 65 | M | Tongue | Patches, plaques > tumors (15% BSA) | Brentuximab vedotin | Brentuximab vedotin | Complete resolution of oral lesions, improvement of skin lesions |
| 7 | Robinson et al. (2020) (current case) | 61 | 61 | M | Upper lip | Patches, plaques > tumors (35% BSA) | Local radiation therapy | Topical mechloramine gel, clobetasol ointment, triamcinolone ointment | Resolution of lip lesion, slow progression of skin lesions |
BSA, Body surface area; Dx, diagnosis; IFN, interferon; PUVA, psoralen ultraviolet-A; TSEB, total skin electron beam.